Archimedic Blog

Are Investigational Device Exemption (IDE) trials a burden or asset?

Truth is, they can be either, depending on how they're designed.

Ask most device teams about IDE trials, and you'll hear about bu...

A Memphis gynecologist was sentenced to 20 years in federal prison for performing more than 15,000 hysteroscopy procedures on women using dirty, reused single-use devices.

He bought fewer than 200 ne...

If you are an early-stage medtech founder who thinks a $335 million exit has nothing to teach you, this one is worth five minutes of your time.

In 2026, Artivion, Inc. paid $135 million upfront, with u...

Are you adapting an existing quality system from QSR to QMSR/ISO 13485?

If so, you're not alone, and you may be finding that the transition isn’t completely seamless.

To bring everyone up to speed, ...

Is your product a medical device…or is it not?

It is a seemingly simple question. However, we often talk with innovators who are unsure about the answer.

The ramifications are real, and often existe...

MedTech Innovator announced its 2026 accelerator cohort. Congrats if you're one of the lucky few! 65 companies were selected from 1,835 applicants. MTI has a 93% ten-year survival rate among alumni, a...

FDA clearance is not the finish line.

Most founders know that. What fewer plan for is that it might not even be a pit stop with a defined length. As any F1 fan will tell you, an unexpected pit stop of ...

Should a small BioTech or MedTech startup spend precious time and resources developing a corporate mission and core values? The answer is 100%, absolutely, unequivocally, YES.

A clearly stated missio...

Olympus Corporation just agreed to pay $270 million for a balloon filled with saline… Take a moment with that.

At $14.5 million in sales, that’s more than an 18x on a times-revenue basis. For what is, ...

Raising funds for a MedTech startup isn’t just about pitching investors—it’s about building relationships, gathering insights, and positioning your innovation for long-term success. In a recent Linked...

It’s been just over a year since I joined Robin Hood Ventures as an angel investor. While many investors in the group are far more seasoned, I’ve gained invaluable insights by diving into the due dili...

I had the privilege of interviewing the Value Analysis Whisperer himself, Mark Copeland, who cracked open the black box of Value Analysis Committees and shared the secrets that MedTech companies need ...